PubMed
Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin
Winbanks et al., 2009
Healing & RecoveryResearch Only — Extreme CautionB
Follistatin 344
FST344 / Myostatin Inhibitor
Follistatin 344 is an isoform of follistatin (FST), a naturally occurring glycoprotein that binds and neutralizes TGF-β superfamily members, most notably myostatin (GDF-8) and activin A. Animal studies show dramatic and permanent muscle hypertrophy with single gene therapy doses. Human pharmacokinetic and safety data are extremely limited; the risk of irreversible muscular hypertrophy and unknown off-target effects make this highly experimental. Research only — extreme caution advised.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 6
- Research grade
- B
- Experience
- 100
- Activity
- 83
Overall check-ins
Trackers & reports
Overview
About Follistatin 344
Follistatin 344 is an isoform of follistatin (FST), a naturally occurring glycoprotein that binds and neutralizes TGF-β superfamily members, most notably myostatin (GDF-8) and activin A. Animal studies show dramatic and permanent muscle hypertrophy with single gene therapy doses. Human pharmacokinetic and safety data are extremely limited; the risk of irreversible muscular hypertrophy and unknown off-target effects make this highly experimental. Research only — extreme caution advised.
- Category
- Healing & Recovery
- Regulatory status
- Research Only — Extreme Caution
- Also known as
- FST344 / Myostatin Inhibitor
- Self-reports
- 6
Community
What 6 users report
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Sleep
6
Energy
3
Self-reported dose per injection
Median bucket: 50–100 mcg · Most common: 50–100 mcg
Reports span 50–200 mcg
50–100
4
100–200
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Research
Cited research (5)
Source
ClinicalTrials.gov
Follistatin / Myostatin inhibition studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis
Sugiyama et al., 2010
PubMed
Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy
Sepulveda et al., 2015
PubMed
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
Stefanakis et al., 2024
Tools
Explore more
Explore
More ways to learn about Follistatin 344 from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Follistatin 344?
This page summarizes 6 anonymized self-reports from PeptIQ users who track Follistatin 344, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Follistatin 344?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Follistatin 344?
5 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Follistatin 344 safe to use?
This wiki does not assess safety or recommend use. Follistatin 344 is listed as Research Only — Extreme Caution. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Follistatin 344?
Research, primarily in animal models, suggests Follistatin 344 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Follistatin 344?
Follistatin 344 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Follistatin 344 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Follistatin 344?
The safety and effectiveness of Follistatin 344 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Follistatin 344?
While there are over 200 published studies on Follistatin 344, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source